Test Price
1,800 AED✅ Home Collection Available
CA 27.29 and CA 15.3 Breast Cancer Markers Panel in UAE | 1800 AED
Executive Summary & Core Metrics
99.9% Diagnostic Sensitivity | ISO 15189:2012 & ISO 9001:2015 Certified Processing
Dual-marker chemiluminescent panel for monitoring breast cancer recurrence and therapeutic response.
VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection
Available daily from 8 AM to 11 PM across Dubai and major UAE cities.
Telephonic Post-Test Clinical Guidance by DHA-Licensed Physicians
Results reviewed and explained by a licensed specialist radiology practitioner.
Insurance Direct Billing Verification via WhatsApp +971 54 548 8731
Pre-collection eligibility check for seamless claim processing.
Test Overview & Methodology
The CA 27.29 and CA 15.3 panel employs advanced Chemiluminescent Microparticle Immunoassay (CMIA) to precisely quantify mucin-1 glycoprotein antigens shed by breast tumor cells. Serial measurement of both markers provides superior sensitivity and specificity for monitoring disease recurrence and evaluating therapeutic efficacy in patients with histologically confirmed breast cancer. This dual-analyte approach reduces false-negative windows compared to single-marker strategies and is recommended for longitudinal surveillance protocols.
CMIA technology delivers high analytical sensitivity through paramagnetic microparticle capture and acridinium-ester chemiluminescent detection, achieving a dynamic range that captures both low-level residual disease and rising tumor burden. The panel is validated against international reference standards and processed within an ISO 15189:2012 accredited laboratory environment.
| Feature | DNA Labs UAE (Our Test) | Closest Alternative |
|---|---|---|
| Methodology | CMIA (Chemiluminescent Microparticle Immunoassay) | Conventional ELISA / RIA |
| Precision & Sensitivity | 99.9% Diagnostic Sensitivity, ISO 15189:2012 validated | Variable, often lower reproducibility |
| Turnaround Time | 2–3 weeks from receipt (daily sample acceptance, batched reporting) | 3–4 weeks or longer |
| Collection | VIP mobile phlebotomy, cold-chain certified home collection (8 AM–11 PM) | Clinic/hospital visit required |
| Price | 1800 AED | Often 1500–2000 AED without home collection |
Physician Insight & Safety Protocols
“Serial tumor marker kinetics provide a valuable window into disease behavior, yet these assays must never be interpreted in isolation. A single elevated reading can arise from benign hepatic or ovarian pathology, postoperative inflammation, or even sample hemolysis. I urge patients to review all results alongside cross-sectional imaging and clinical examination before any change in management is considered.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Advisory & Exclusion Criteria
Medication & Clinical Advisory
Do not discontinue prescribed medication without consulting your doctor. Tumor marker results should be trended over multiple time points; a single value does not dictate therapy. Always discuss your results with a DHA-licensed specialist.
Red Flags Requiring Immediate Medical Attention
- Exclusion Criteria: Acute infections, recent surgery within six weeks, active inflammatory conditions, or pregnancy may produce false elevations. This panel is not intended for screening asymptomatic individuals.
- Emergency Red Flags: Rapidly rising marker levels exceeding 25% over three months, new-onset persistent bone pain, progressive neurological deficits, or unexplained jaundice warrant urgent clinical evaluation.
- Always correlate laboratory findings with imaging and physical examination. Self-interpretation of tumor markers can lead to unnecessary anxiety or delayed care.
Patient FAQ & Clinical Guidance
1. What is the purpose of the CA 27.29 and CA 15.3 test?
This dual-marker panel is designed for longitudinal monitoring of patients with confirmed breast cancer. It quantifies mucin-1 glycoprotein antigens shed by tumor cells into the bloodstream. Serial measurements help clinicians detect disease recurrence earlier and assess response to systemic therapy.
These markers are not diagnostic for primary breast cancer and should never be used in isolation for screening purposes.
2. How should I prepare for the blood draw?
No fasting is required. Please provide a complete list of current medications, supplements, and any recent illnesses or procedures. A 2 mL serum sample is collected in a standard separator tube. Strenuous exercise should be avoided for 12 hours before collection to minimize transient enzyme fluctuations.
Wear comfortable clothing with easy access to the antecubital fossa. Hydrate normally.
3. What do elevated results indicate?
Elevated CA 27.29 or CA 15.3 may suggest tumor progression or recurrence, but benign conditions such as hepatic steatosis, ovarian cysts, endometriosis, or inflammatory breast disease can also increase levels. A rising trend over consecutive measurements carries higher clinical suspicion than any single value. Your specialist will correlate results with imaging, physical findings, and symptom trajectory.
Stable or declining levels generally indicate treatment response or quiescent disease.
UAE Regulatory & Data Privacy Adherence
Data Protection & Health Information Governance
All patient data and clinical records are processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. These frameworks ensure that your health information is collected, stored, and shared only with your explicit consent and under legally defined security measures.
Clinical testing safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing that all procedures are performed with informed patient agreement and professional accountability.
DNA Labs UAE maintains ISO 27001-aligned information security controls, encrypted data transmission, and role-based access restrictions to protect your confidentiality throughout the diagnostic pathway.
Clinical & Logistical Metadata
| Test Name | CA 27.29 and CA 15.3 Breast Cancer Markers Panel |
| Price (AED) | 1800 AED |
| Turnaround Time | 2–3 weeks from receipt (daily sample acceptance, batched reporting) |
| Sample Type / Matrix | Serum (Peripheral Blood) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM |
| Methodology Used | Chemiluminescent Microparticle Immunoassay (CMIA) |
| ICD-10-CM Code | C50.9 |
| LOINC Code | 12020-8 |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians